NJ State Employees Deferred Compensation Plan purchased a new stake in shares of Pharmerica Corporation (NYSE:PMC) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 10,000 shares of the company’s stock, valued at approximately $293,000.
Other hedge funds have also made changes to their positions in the company. Russell Investments Group Ltd. lifted its stake in Pharmerica Corporation by 124.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 4,886 shares of the company’s stock worth $128,000 after purchasing an additional 2,710 shares in the last quarter. Public Employees Retirement System of Ohio lifted its stake in Pharmerica Corporation by 10.5% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 5,028 shares of the company’s stock worth $132,000 after purchasing an additional 476 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Pharmerica Corporation in the 1st quarter worth approximately $121,000. State of Alaska Department of Revenue lifted its stake in Pharmerica Corporation by 79.8% in the 2nd quarter. State of Alaska Department of Revenue now owns 6,112 shares of the company’s stock worth $160,000 after purchasing an additional 2,712 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in Pharmerica Corporation in the 2nd quarter worth approximately $200,000. Institutional investors own 86.49% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “NJ State Employees Deferred Compensation Plan Buys New Stake in Pharmerica Corporation (PMC)” was posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.truebluetribune.com/2017/11/14/nj-state-employees-deferred-compensation-plan-takes-position-in-pharmerica-corporation-pmc.html.
PMC has been the topic of several research reports. Zacks Investment Research cut shares of Pharmerica Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. BidaskClub cut shares of Pharmerica Corporation from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. KeyCorp cut shares of Pharmerica Corporation to an “overweight” rating in a research report on Wednesday, August 2nd. Barrington Research lowered shares of Pharmerica Corporation from an “outperform” rating to an “underperform” rating in a report on Thursday, August 3rd. Finally, UBS AG reaffirmed a “neutral” rating and set a $29.25 target price (up previously from $26.00) on shares of Pharmerica Corporation in a report on Thursday, August 3rd. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. Pharmerica Corporation currently has a consensus rating of “Hold” and a consensus target price of $30.50.
Shares of Pharmerica Corporation (PMC) opened at $29.15 on Tuesday. Pharmerica Corporation has a twelve month low of $22.00 and a twelve month high of $29.50. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.58 and a quick ratio of 1.79. The stock has a market cap of $905.60, a price-to-earnings ratio of 15.08, a price-to-earnings-growth ratio of 1.27 and a beta of 0.82.
Pharmerica Corporation (NYSE:PMC) last posted its earnings results on Thursday, November 9th. The company reported $0.46 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.49 by ($0.03). Pharmerica Corporation had a return on equity of 10.94% and a net margin of 0.83%. The company had revenue of $595.10 million during the quarter, compared to analysts’ expectations of $596.80 million. equities analysts expect that Pharmerica Corporation will post 1.92 earnings per share for the current year.
Pharmerica Corporation Company Profile
Receive News & Ratings for Pharmerica Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmerica Corporation and related companies with MarketBeat.com's FREE daily email newsletter.